Top

Published in:

01-04-2018 | Original Paper

Circulating Hormones and Mammographic Density in Premenopausal Women

Authors: Kimberly A. Bertrand, A. Heather Eliassen, Susan E. Hankinson, Bernard A. Rosner, Rulla M. Tamimi

Published in: Discover Oncology | Issue 2/2018

Abstract

Prior research suggests that several endogenous hormones in premenopausal women are associated with breast cancer risk; however, few studies have evaluated associations of endogenous hormones with mammographic density (MD) in premenopausal women. We conducted a cross-sectional study of plasma hormone levels in relation to MD among 634 cancer-free premenopausal women in the Nurses’ Health Study II. We measured percent MD from screening mammograms using a computer-assisted method. We assayed estradiol, estrone, and estrone sulfate in blood samples timed in early follicular and mid-luteal phases of the menstrual cycle as well as testosterone, androstenedione, progesterone, dehydroepiandrosterone (DHEA), DHEA sulfate, sex hormone–binding globulin (SHBG), and anti-Müllerian hormone in luteal or untimed samples. We used multivariable linear regression to quantify the association of %MD with quartiles of each hormone, adjusting for age, body mass index, and breast cancer risk factors. Women in the highest quartile of follicular estradiol levels had significantly greater %MD compared to those in the lowest quartile [difference, 6.7 percentage points; 95% confidence interval (CI) 2.2, 11.3; p-trend < 0.001]. Similar associations were observed for follicular free estradiol but not luteal-phase estradiol. Also, women in the top (vs. bottom) quartile of free testosterone had significantly lower %MD (difference, − 4.7; 95% CI − 8.7, − 0.8; p-trend = 0.04). Higher SHBG was significantly associated with higher percent MD (difference, 4.8; 95% CI 1.1, 8.6; p-trend = 0.002). Percent MD was not strongly associated with other measured hormones. Results were similar in analyses that excluded women with anovulatory cycles. Our findings suggest that follicular estradiol and SHBG may play an important role in premenopausal percent MD.

Available only for authorised users

Endogenous H, Breast Cancer Collaborative G, Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V et al (2013) Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 14(10):1009–1019CrossRef

Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjønneland A, Olsen A, Overvad K, Clavel-Chapelon F, Dossus L, Baglietto L, Rinaldi S, Chajes V, Romieu I, Boeing H, Schütze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Tumino R, Ricceri F, Mattiello A, Buckland G, Ramón Quirós J, Sánchez MJ, Amiano P, Chirlaque MD, Barricarte A, Bas Bueno-de-Mesquita H, van Gils CH, Peeters PH, Andersson A, Sund M, Weiderpass E, Khaw KT, Wareham N, Key TJ, Travis RC, Merritt MA, Gunter MJ, Riboli E, Lukanova A (2014) Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—results from the EPIC cohort. Int J Cancer 134(8):1947–1957. https://doi.org/10.1002/ijc.28528 CrossRefPubMed

Fortner RT, Eliassen AH, Spiegelman D, Willett WC, Barbieri RL, Hankinson SE (2013) Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses’ Health Study II. Breast Cancer Res 15(2):R19. https://doi.org/10.1186/bcr3394 CrossRefPubMedPubMedCentral

McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15(6):1159–1169. https://doi.org/10.1158/1055-9965.EPI-06-0034 CrossRef

Martin LJ, Boyd NF (2008) Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 10(1):201. https://doi.org/10.1186/bcr1831 CrossRefPubMedPubMedCentral

Boyd NF, Stone J, Martin LJ, Jong R, Fishell E, Yaffe M, Hammond G, Minkin S (2002) The association of breast mitogens with mammographic densities. Br J Cancer 87(8):876–882. https://doi.org/10.1038/sj.bjc.6600537 CrossRefPubMedPubMedCentral

Aiello EJ, Tworoger SS, Yasui Y, Stanczyk FZ, Potter J, Ulrich CM, Irwin M, McTiernan A (2005) Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomark Prev 14(6):1411–1417. https://doi.org/10.1158/1055-9965.EPI-04-0920 CrossRef

Tamimi RM, Hankinson SE, Colditz GA, Byrne C (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev 14(11 Pt 1):2641–2647. https://doi.org/10.1158/1055-9965.EPI-05-0558 CrossRef

Greendale GA, Palla SL, Ursin G, Laughlin GA, Crandall C, Pike MC, Reboussin BA (2005) The association of endogenous sex steroids and sex steroid binding proteins with mammographic density: results from the postmenopausal estrogen/progestin interventions mammographic density study. Am J Epidemiol 162(9):826–834. https://doi.org/10.1093/aje/kwi286 CrossRefPubMed

10.

Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkerd E, Healey CS, Dunning A, Doody D, Ponder B et al (2006) Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women. Cancer Epidemiol Biomark Prev 15(8):1502–1508. https://doi.org/10.1158/1055-9965.EPI-05-0828 CrossRef

11.

Bertrand KA, Eliassen AH, Hankinson SE, Gierach GL, Xu X, Rosner B, Ziegler RG, Tamimi RM (2012) Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women. Breast Cancer Res Treat 136(1):277–287. https://doi.org/10.1007/s10549-012-2240-0 CrossRefPubMedPubMedCentral

12.

Gierach GL, Patel DA, Falk RT, Pfeiffer RM, Geller BM, Vacek PM, Weaver DL, Chicoine RE, Shepherd JA, Mahmoudzadeh AP, Wang J, Fan B, Herschorn SD, Xu X, Veenstra T, Fuhrman B, Sherman ME, Brinton LA (2015) Relationship of serum estrogens and metabolites with area and volume mammographic densities. Horm Cancer 6(2–3):107–119. https://doi.org/10.1007/s12672-015-0216-3 CrossRefPubMedPubMedCentral

13.

Walker K, Fletcher O, Johnson N, Coupland B, McCormack VA, Folkerd E, Gibson L, Hillier SG, Holly JM, Moss S, Dowsett M, Peto J, dos Santos Silva I (2009) Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors. Cancer Res 69(16):6490–6499. https://doi.org/10.1158/0008-5472.CAN-09-0280 CrossRefPubMed

14.

Jung S, Stanczyk FZ, Egleston BL, Snetselaar LG, Stevens VJ, Shepherd JA, Van Horn L, LeBlanc ES, Paris K, Klifa C, Dorgan JF (2015) Endogenous sex hormones and breast density in young women. Cancer Epidemiol Biomark Prev 24(2):369–378. https://doi.org/10.1158/1055-9965.EPI-14-0939 CrossRef

15.

Yong M, Atkinson C, Newton KM, Aiello Bowles EJ, Stanczyk FZ, Westerlind KC, Holt VL, Schwartz SM, Leisenring WM, Lampe JW (2009) Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women. Cancer Causes Control 20(7):1039–1053. https://doi.org/10.1007/s10552-009-9321-3 CrossRefPubMedPubMedCentral

16.

Iversen A, Frydenberg H, Furberg AS, Flote VG, Finstad SE, McTiernan A, Ursin G, Wilsgaard T, Ellison PT, Jasienska G, Thune I (2016) Cyclic endogenous estrogen and progesterone vary by mammographic density phenotypes in premenopausal women. Eur J Cancer Prev 25(1):9–18. https://doi.org/10.1097/CEJ.0000000000000130 CrossRefPubMed

17.

Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ (2006) Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast 15(1):20–28. https://doi.org/10.1016/j.breast.2005.04.014 CrossRefPubMed

18.

Borugian MJ, Spinelli JJ, Gordon PB, Abanto Z, Brooks-Wilson A, Pollak MN, Warren LJ, Hislop TG, Gallagher RP (2014) Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada). Cancer Causes Control 25(3):385–394. https://doi.org/10.1007/s10552-014-0339-9 CrossRefPubMed

19.

Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF (2015) Adolescent endogenous sex hormones and breast density in early adulthood. Breast Cancer Res 17(1):77. https://doi.org/10.1186/s13058-015-0581-4 CrossRefPubMedPubMedCentral

20.

Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF (2016) Early life body fatness, serum anti-Mullerian hormone, and breast density in young adult women. Cancer Epidemiol Biomark Prev 25(7):1151–1157. https://doi.org/10.1158/1055-9965.EPI-16-0185 CrossRef

21.

Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, Spittle CS, Godwin AK, Brinton LA (2009) Prospective case–control study of serum Mullerian inhibiting substance and breast cancer risk. J Natl Cancer Inst 101(21):1501–1509. https://doi.org/10.1093/jnci/djp331 CrossRefPubMedPubMedCentral

22.

Nichols HB, Baird DD, Stanczyk FZ, Steiner AZ, Troester MA, Whitworth KW, Sandler DP (2015) Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk. Cancer Prev Res (Phila) 8(6):528–534. https://doi.org/10.1158/1940-6207.CAPR-14-0377 CrossRef

23.

Eliassen AH, Zeleniuch-Jacquotte A, Rosner B, Hankinson SE (2016) Plasma anti-Mullerian hormone concentrations and risk of breast cancer among premenopausal women in the Nurses’ health studies. Cancer Epidemiol Biomark Prev 25(5):854–860. https://doi.org/10.1158/1055-9965.EPI-15-1240 CrossRef

24.

Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98(19):1406–1415. https://doi.org/10.1093/jnci/djj376 CrossRefPubMed

25.

Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476–2482. https://doi.org/10.1158/0008-5472.CAN-05-3369 CrossRefPubMed

26.

Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE (2006) The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomark Prev 15(5):967–971. https://doi.org/10.1158/1055-9965.EPI-05-0976 CrossRef

27.

Byng JW, Boyd NF, Little L, Lockwood G, Fishell E, Jong RA, Yaffe MJ (1996) Symmetry of projection in the quantitative analysis of mammographic images. Eur J Cancer Prev 5(5):319–327. https://doi.org/10.1097/00008469-199610000-00003 CrossRefPubMed

28.

Pettersson A, Hankinson SE, Willett WC, Lagiou P, Trichopoulos D, Tamimi RM (2011) Nondense mammographic area and risk of breast cancer. Breast Cancer Res 13(5):R100. https://doi.org/10.1186/bcr3041 CrossRefPubMedPubMedCentral

29.

Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167(6):653–666. https://doi.org/10.1093/aje/kwm348 CrossRefPubMed

30.

Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60(14):3744–3748PubMed

31.

Stone J, Ding J, Warren RM, Duffy SW, Hopper JL (2010) Using mammographic density to predict breast cancer risk: dense area or percentage dense area. Breast Cancer Res 12(6):R97. https://doi.org/10.1186/bcr2778 CrossRefPubMedPubMedCentral

32.

Lokate M, Peeters PH, Peelen LM, Haars G, Veldhuis WB, van Gils CH (2011) Mammographic density and breast cancer risk: the role of the fat surrounding the fibroglandular tissue. Breast Cancer Res 13(5):R103. https://doi.org/10.1186/bcr3044 CrossRefPubMedPubMedCentral

33.

Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, Vachon C, Bakker MF, Giles GG, Chia KS et al (2014) Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst

34.

Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE (1998) Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 90(17):1292–1299. https://doi.org/10.1093/jnci/90.17.1292 CrossRefPubMed

35.

Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96(24):1856–1865. https://doi.org/10.1093/jnci/djh336 CrossRefPubMed

36.

Hirko KA, Spiegelman D, Willett WC, Hankinson SE, Eliassen AH (2014) Alcohol consumption in relation to plasma sex hormones, prolactin, and sex hormone-binding globulin in premenopausal women. Cancer Epidemiol Biomark Prev 23(12):2943–2953. https://doi.org/10.1158/1055-9965.EPI-14-0982 CrossRef

37.

Södergård R, Bäckström T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16(6):801–810. https://doi.org/10.1016/0022-4731(82)90038-3 CrossRefPubMed

38.

Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE (2006) Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol Biomark Prev 15(5):972–978. https://doi.org/10.1158/1055-9965.EPI-05-0848 CrossRef

39.

Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA (2000) Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11(7):653–662. https://doi.org/10.1023/A:1008926607428 CrossRefPubMed

40.

Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL (1998) The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer 78(9):1233–1238. https://doi.org/10.1038/bjc.1998.660 CrossRefPubMedPubMedCentral

41.

Samimi G, Colditz GA, Baer HJ, Tamimi RM (2008) Measures of energy balance and mammographic density in the Nurses’ Health Study. Breast Cancer Res Treat 109(1):113–122. https://doi.org/10.1007/s10549-007-9631-7 CrossRefPubMed

42.

Durrleman S, Simon R (1989) Flexible regression models with cubic splines. Stat Med 8(5):551–561. https://doi.org/10.1002/sim.4780080504 CrossRefPubMed

43.

Linton L, Taylor M, Dunn S, Martin L, Chavez S, Stanitz G, Huszti E, Minkin S, Boyd N (2016) Associations of serum levels of sex hormones in follicular and luteal phases of the menstrual cycle with breast tissue characteristics in young women. PLoS One 11(10):e0163865. https://doi.org/10.1371/journal.pone.0163865 CrossRefPubMedPubMedCentral

44.

Somboonporn W, Davis SR, National H, Medical Research C (2004) Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 25(3):374–388. https://doi.org/10.1210/er.2003-0016 CrossRefPubMed

45.

Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O, Labate AM (1997) Determinants of sex hormone-binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Virgilio-menopause-health group. Metabolism 46(1):5–9. https://doi.org/10.1016/S0026-0495(97)90159-1 CrossRefPubMed

46.

Dupont J, Le Roith D (2001) Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol 54(3):149–154. https://doi.org/10.1136/mp.54.3.149 CrossRefPubMedPubMedCentral

47.

Hamelers IH, Steenbergh PH (2003) Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 10(2):331–345. https://doi.org/10.1677/erc.0.0100331 CrossRefPubMed

48.

Frydenberg H, Flote VG, Iversen A, Finstad SE, Furberg AS, Torjesen PA, Wilsgaard T, Schlichting E, Ellison PT, Ursin G, Thune I (2014) Insulin-like growth factor-1, growth hormone, and daily cycling estrogen are associated with mammographic density in premenopausal women. Cancer Causes Control 25(7):891–903. https://doi.org/10.1007/s10552-014-0389-z CrossRefPubMed

49.

Schernhammer ES, Tworoger SS, Eliassen AH, Missmer SA, Holly JM, Pollak MN, Hankinson SE (2007) Body shape throughout life and correlations with IGFs and GH. Endocr Relat Cancer 14(3):721–732. https://doi.org/10.1677/ERC-06-0080 CrossRefPubMed

50.

Rice MS, Tamimi RM, Connolly JL, Collins LC, Shen D, Pollak MN, Rosner B, Hankinson SE, Tworoger SS (2012) Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses’ Health Study II. Breast Cancer Res 14(2):R44. https://doi.org/10.1186/bcr3141 CrossRefPubMedPubMedCentral

51.

Graham SJ, Stanchev PL, Lloyd-Smith JO, Bronskill MJ, Plewes DB (1995) Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging 5(6):695–701. https://doi.org/10.1002/jmri.1880050613 CrossRefPubMed

52.

White E, Velentgas P, Mandelson MT, Lehman CD, Elmore JG, Porter P, Yasui Y, Taplin SH (1998) Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 90(12):906–910. https://doi.org/10.1093/jnci/90.12.906 CrossRefPubMed

Title: Circulating Hormones and Mammographic Density in Premenopausal Women
Authors: Kimberly A. Bertrand
A. Heather Eliassen
Susan E. Hankinson
Bernard A. Rosner
Rulla M. Tamimi
Publication date: 01-04-2018
Publisher: Springer US
Published in: Discover Oncology / Issue 2/2018
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-017-0321-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Circulating Hormones and Mammographic Density in Premenopausal Women

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

Urban Neighborhood and Residential Factors Associated with Breast Cancer in African American Women: a Systematic Review

Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer

Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models

The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer

Harnessing a Different Dependency: How to Identify and Target Androgen Receptor-Positive Versus Quadruple-Negative Breast Cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page